Amgen Stemgen

Executive Summary

FDA Biological Response Modifiers Advisory Committee will review BLA 97-0509 for Stemgen (ancestim) in combination with Amgen's Neupogen (filgrastim) for mobilization of peripheral blood progenitor cells on July 30. The committee will also discuss the report from the Dec. 17 meeting of the Xenotransplantation Subcommittee and the research programs in the Center for Biologics Evaluation & Research's Laboratory of Immunology and Laboratory of Molecular Immunology. The meeting will be at the Holiday Inn in Bethesda, Md. at 8 a.m...